Eli Lilly and Co
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
The lucrative market for weight loss drugs won’t stay a duopoly forever. With billions at stake, that’s pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. But the reality of the coming competition has grown more tangible after recent announcements from rival drugmakers Roche and […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a “very powerful duopoly.” “But […]
Read More
Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial
Weight loss drug concept. Cr | Istock | Getty Images Shares of Viking Therapeutics jumped 16% in premarket trading Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. It brings the San Diego-based company one step closer to joining the […]
Read More
CNBC Daily Open: Rising geopolitical risk
Traders work on the floor of the New York Stock Exchange during afternoon trading on April 09, 2024 in New York City. Michael M. Santiago | Getty Images This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no […]
Read More
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate. The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market. Roche shares jumped in […]
Read More
Healthy Returns: Diabetes drug Ozempic may lower dementia risk, nicotine use
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Novo Nordisk‘s blockbuster diabetes drug Ozempic may have more to offer beyond […]
Read More
CNBC Pro Talks: From weight loss drugs to AI winners, CIO set to reveal his top stocks
Weight loss drugs and artificial intelligence have been dominating headlines, with investors betting that stocks in both categories have big potential upside. On Wednesday’s Pro Talks , CNBC’s Senior Technology Correspondent Arjun Kharpal will ask Tema ETFs’ Yuri Khodjamirian how to best invest in these areas and more. Got a question for Khodjamirian? Submit it […]
Read More
Healthy Returns: Drugmakers are racing to develop more convenient weight loss pills
Aykut Karahan | Istock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Several drugmakers are hurrying to capitalize on one of the next major innovations coming to the booming weight loss drug market: effective, convenient and potentially affordable obesity pills. Most of the […]
Read More
Pfizer moves forward with once-daily version of weight loss pill after setbacks
Sopa Images | Lightrocket | Getty Images Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw “encouraging” data in an ongoing early-stage trial. The company evaluated several once-daily formulations of the drug and identified one with “the most favorable profile.” Pfizer said it […]
Read More